Patients treated with bivalirudin still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomized clinical trials of bivalirudin and heparin for percutaneous coronary interventions.

CONCLUSIONS: Advantages of bivalirudin are undoubtedly related to GPI use in the heparin arms. Bivalirudin-based regimens are more beneficial when compared with heparin and planned GPI use in terms of NACE and major bleedings. It was not observed when compared to heparin and provisional GPI use. Regardless of adjunctive GPI use, stent thrombosis episodes were significantly more common in bivalirudin treated subjects. Therefore the safety and economic issues may urge revision of this aspect of current clinical practice and guidelines. PMID: 29350380 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research